Details for Patent: 8,541,425
✉ Email this page to a colleague
Title: | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Abstract: | The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. |
Inventor(s): | Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Wilmington, DE), Fridman; Jordan S. (Newark, DE), Vaddi; Krishna (Kennett Square, PA) |
Assignee: | Incyte Corporation (Wilmington, DE) |
Filing Date: | Aug 27, 2009 |
Application Number: | 12/549,170 |
Claims: | 1. A method of treating a disease in a patient, wherein said disease is selected from cachexia, acute myelogenous leukemia, acute lymphoblastic leukemia, and chronic myelomonocytic leukemia, comprising administering to said patient a therapeutically effective amount of a compound which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]prop- anenitrile, or a pharmaceutically acceptable salt thereof, wherein said treating refers to ameliorating or inhibiting the disease in the patient. 2. The method according to claim 1, wherein said compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl- ]propanenitrile, or a pharmaceutically acceptable salt thereof. 3. The method according to claim 2, wherein said disease is acute myelogenous leukemia. 4. The method according to claim 2, wherein said disease is chronic myelomonocytic leukemia. 5. The method according to claim 2, wherein said disease is cachexia. 6. The method according to claim 5, wherein said cachexia results from or is associated with cancer. 7. The method according to claim 2, wherein said disease is acute lymphoblastic leukemia. |